AR 42

Drug Profile

AR 42

Alternative Names: AR-42; HDAC-42; NSC-D736012; OSU-HDAC42

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Deacetylase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Lymphoma; Multiple myeloma; Solid tumours
  • Phase I Acute myeloid leukaemia; Renal cell carcinoma; Soft tissue sarcoma
  • Phase 0 Meningioma; Neurilemmoma
  • Preclinical Bladder cancer

Most Recent Events

  • 22 Nov 2016 Arno Therapeutics suspends a phase I trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Recurrent, Inoperable/Unresectable, Metastatic disease) in USA (PO) (NCT02795819)
  • 22 Nov 2016 Arno Therapeutics suspends a phase I trial in Soft tissue sarcoma (Combination therapy, Late-stage disease, Recurrent, Inoperable/Unresectable, Metastatic disease) in USA (PO) (NCT02795819)
  • 01 Jul 2016 Phase-I clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Recurrent, Inoperable/Unresectable, Metastatic disease) in USA (PO) (NCT02795819)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top